Reduction of Progesterone Elevation at Trigger in POR After Long Acting COS Compared With Daily COS: a Prospective Randomized Trial (PE-PMA)
Primary Purpose
Infertility
Status
Unknown status
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Corifollitropin alfa
Follitropin Beta
Sponsored by
About this trial
This is an interventional prevention trial for Infertility
Eligibility Criteria
Inclusion Criteria:
- Indication to IVF treatment
- Normal BMI (18.5-24.9 kg/m2)
- AMH level < 1.1 ng/ml and/or AFC < 5 follicles and/or < 3 oo-cytes retrieved in previous cycle
- Regular menstrual cycles
- Signed informed consent
Exclusion Criteria:
- Freeze all cycles for abnormal bleeding
- PCOS
- History of untreated autoimmune
- Endocrine or metabolic disorders
- Ovarian cystectomy or oophorectomy
- FSH ≥ 20 lU/L
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Corifollitropin alpha group
FSH group
Arm Description
Patients treated with Corifollitropin-alpha in a long-acting controlled ovarian stimulation
Patients treated with Follitropin beta in a daily controlled ovarian stimulation protocol
Outcomes
Primary Outcome Measures
Premature progesterone elevation
Progesterone > or equal to 1.1 ng/mL at day of trigger
Secondary Outcome Measures
Percentage of freeze-all cycles due to premature progesterone elevation
Number of oocytes collected at ovum retrieval
Fertilization rate
Percentage of oocytes fertilized
Number of embryos available
Pregnancy rate
Beta-HCG positive
Ongoing pregnancy
Vital fetus at 20 weeks of gestation
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04695483
Brief Title
Reduction of Progesterone Elevation at Trigger in POR After Long Acting COS Compared With Daily COS: a Prospective Randomized Trial
Acronym
PE-PMA
Official Title
Reduction of Progesterone Elevation at Trigger in Poor Responder Bologna' Criteria Patients After Controlled Ovarian Stimulation With Long Acting Standard Stimulation Protocol Compared With Conventional Daily Protocol: a Single Center Prospective Randomized Fase IV Trial
Study Type
Interventional
2. Study Status
Record Verification Date
December 2020
Overall Recruitment Status
Unknown status
Study Start Date
March 7, 2021 (Anticipated)
Primary Completion Date
August 30, 2022 (Anticipated)
Study Completion Date
February 28, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
IRCCS San Raffaele
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The overarching objective of this research is to generate clinical evidence to argue the benefits of long acting stimulation protocol compared to the daily stimulation protocol in poor ovarian responder bologna' criteria patients after controlled ovarian stimulation. Reduction in the proportion of subjects with progesterone > 1.1 ng/ml on the day of triggering (day + 13) in the experimental group compared to the control group is expected.
Detailed Description
Each patient will receive a first visit for infertility where will be collected subject history and baseline information, and meet all the inclusion / exclusion criteria. Eligible patients who agreed to participate will be randomized to either long acting standard COS with corifollitropin alpha or standard COS with daily FSH in a fixed GnRH antagonist protocol. All patients will be allowed to participate in the study only once and a written informed consent will be obtained from all, following consultation and before the initiation of the treatment.
The endocrine profile of all the patients will be evaluated by analysis of serum progesterone, 17b-estradiol (E2), FSH and LH at different time points: basal condition, during stimulation, at the hCG day and at pick-up.
Transvaginal follicular aspiration will be performed by ultrasound guidance 36 hours after hCG administration. The day of pick up oocytes will be fertilized with partner's semen; after 3-5 days, on the base of its evolution, embryo will be transferred. 14 days after embryo-transfer a preg-nancy test will be performed. Follow up in case of obtained pregnancy will be done until 20 weeks of gestation and considered as ongoing pregnancy.
The entire duration of the study is 24 months, the follow up of the last patients enrolled will be 6 months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
110 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Corifollitropin alpha group
Arm Type
Experimental
Arm Description
Patients treated with Corifollitropin-alpha in a long-acting controlled ovarian stimulation
Arm Title
FSH group
Arm Type
Active Comparator
Arm Description
Patients treated with Follitropin beta in a daily controlled ovarian stimulation protocol
Intervention Type
Drug
Intervention Name(s)
Corifollitropin alfa
Intervention Description
Controlled ovarian stimulation long-acting protocol
Intervention Type
Drug
Intervention Name(s)
Follitropin Beta
Intervention Description
Daily controlled ovarian stimulation protocol
Primary Outcome Measure Information:
Title
Premature progesterone elevation
Description
Progesterone > or equal to 1.1 ng/mL at day of trigger
Time Frame
day 12
Secondary Outcome Measure Information:
Title
Percentage of freeze-all cycles due to premature progesterone elevation
Time Frame
day 12
Title
Number of oocytes collected at ovum retrieval
Time Frame
day 14
Title
Fertilization rate
Description
Percentage of oocytes fertilized
Time Frame
day 15
Title
Number of embryos available
Time Frame
Day 17
Title
Pregnancy rate
Description
Beta-HCG positive
Time Frame
day 30
Title
Ongoing pregnancy
Description
Vital fetus at 20 weeks of gestation
Time Frame
Up to 20 weeks
10. Eligibility
Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
42 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Indication to IVF treatment
Normal BMI (18.5-24.9 kg/m2)
AMH level < 1.1 ng/ml and/or AFC < 5 follicles and/or < 3 oo-cytes retrieved in previous cycle
Regular menstrual cycles
Signed informed consent
Exclusion Criteria:
Freeze all cycles for abnormal bleeding
PCOS
History of untreated autoimmune
Endocrine or metabolic disorders
Ovarian cystectomy or oophorectomy
FSH ≥ 20 lU/L
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Enrico Papaleo, MD
Phone
+390226436228
Email
papaleo.enrico@hsr.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Enrico Papaleo, MD
Organizational Affiliation
IRCCS San Raffaele
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Reduction of Progesterone Elevation at Trigger in POR After Long Acting COS Compared With Daily COS: a Prospective Randomized Trial
We'll reach out to this number within 24 hrs